APSR2026-954

Yes
Late-Breaking
Submitted
Poster Presentation
 
AP10-028
P28
 
Format: PPTX Only
https://storage.unitedwebnetwork.com/files/1285/1242903-46904-APSR26_Poster_433922.pdf
Format: PDF Only
07. COPD
2

No more than 15 authors can be listed.
Please ensure the authors are listed in the right order.
If there are multiple affiliations, please use the "+" button next to "Select Country/Region" to add additional affiliation fields.

Yun Feng * Ruijin Hospital, Shanghai Jiao Tong University School of Medicine Department of Pulmonary and Critical Care Medicine Shanghai China
Yifan Lu - Ruijin Hospital, Shanghai Jiao Tong University School of Medicine Department of Pulmonary and Critical Care Medicine Shanghai China
 
 
 
 
 
 
 
 
 
 
 
 
 
Presenting Author Details
Yun
Feng
fy01057@163.com
+8617321113771
41-50
China
Original Research
Dihydromyricetin - Butyric acid - Liposome for Enhanced Treatment of Chronic Obstructive Pulmonary Disease by Ameliorating Oxidative Stress and Suppressing Inflammation Response
Maximum 25 words
Abstract Content
Chronic obstructive pulmonary disease (COPD), the fourth leading cause of death worldwide, is characterized by persistent airflow limitation, oxidative stress, and chronic inflammation. Dihydromyricetin (DMY) possesses antioxidant and anti-inflammatory properties, while butyric acid, a short-chain fatty acid, exhibits anti-inflammatory and metabolic regulatory effects. This study aimed to develop a novel liposomal formulation combining DMY and butyric acid to enhance their therapeutic potential against COPD.
DMY was chemically conjugated with butyric acid through esterification and subsequently encapsulated into liposomes to generate DMY-But-Lipo. The antioxidant activity, cytocompatibility, and anti-inflammatory effects of DMY-But-Lipo were evaluated in vitro using LPS-stimulated macrophages. Therapeutic efficacy was further assessed in a COPD model through bronchoalveolar lavage fluid (BALF) analysis, histopathological examination, pulmonary redox status evaluation, and lung function assessment.
DMY-But-Lipo demonstrated effective free radical scavenging activity and excellent cytocompatibility in vitro. In LPS-stimulated macrophages, it significantly reduced intracellular reactive oxygen species (ROS) production and suppressed the mRNA expression of pro-inflammatory cytokines. In vivo, intranasal administration of DMY-But-Lipo reduced inflammatory cell infiltration in BALF, improved alveolar structural integrity, restored pulmonary redox balance, and enhanced lung function compared with untreated COPD controls.
DMY-But-Lipo effectively alleviates oxidative stress and inflammation in COPD through a liposomal delivery system that integrates the pharmacological advantages of DMY and butyric acid. These findings suggest that DMY-But-Lipo represents a promising therapeutic strategy for COPD treatment.
 
 
 
 
 
No
No
 
JPG or JPEG or PNG format ONLY
Dihydromyricetin, Butyric acid, Liposome, Chronic obstructive pulmonary disease, Pulmonary inflammation
maximum 3 keywords and no abbreviations, separated by commas
 
220